Clinical Trial Update: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia; results were posted for this completed trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (Tasigna) (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2016-03-03